EPS of $0.37 in fiscal 2025's Q1 matched analyst expectations. Revenue for the period jumped 12.4% year over year to $1.15 ...

While I think the sector can continue to perform well with a more friendly regulatory environment and lower interest rates, ...

The Vanguard S&P 500 Growth Index Fund ETF Shares holds positions in top growth stocks on the S&P 500. Over the past decade, ...

AbbVie shares dropped after disappointing results involving one of its clinical trials, but the business itself remains ...

QuantumScape's agreement with PowerCo extends QuantumScape's cash runway by 18 months to 2028, thanks to a $130 million ...

CDs are a safe investment that earn a fixed interest rate. See if they're worth getting in 2025 or if you should find another ...

When it was approved in March 2024, Rezdiffra became the only medicine approved by the Food and Drug Administration (FDA) to ...

Amazon's non-retail services are driving its free cash flow through the roof. Nike is going through tough times, but it's ...

Political fears and a failed clinical trial have soured the market on AbbVie. The market is still punishing Pfizer for its ...

Apple has been treating shareholders to a rising dividend for 13 straight years. The tech giant usually makes dividend ...

Handling higher utility bills can be stressful, but there are ways to save without sacrificing your comfort. Here are three ...

Alphabet is dominant in the advertising world. Google Cloud and AI have a huge role to play in future growth. The stock is ...